NewAmsterdam Pharma (NASDAQ:NAMS) Shares Up 6.7%

Shares of NewAmsterdam Pharma (NASDAQ:NAMS) were up 6.7% during mid-day trading on Tuesday . The stock traded as high as $21.78 and last traded at $21.58. Approximately 22,961 shares traded hands during trading, a decline of 90% from the average daily volume of 240,353 shares. The stock had previously closed at $20.23.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on NAMS shares. Piper Sandler started coverage on NewAmsterdam Pharma in a report on Tuesday, January 16th. They set an “overweight” rating and a $37.00 price objective on the stock. Scotiabank started coverage on NewAmsterdam Pharma in a report on Thursday, March 14th. They set a “sector outperform” rating and a $35.00 price objective on the stock. Guggenheim started coverage on NewAmsterdam Pharma in a report on Thursday, January 18th. They set a “buy” rating and a $30.00 price objective on the stock. Finally, Royal Bank of Canada raised their price objective on NewAmsterdam Pharma from $25.00 to $31.00 and gave the stock an “outperform” rating in a report on Thursday, February 29th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $33.25.

NewAmsterdam Pharma Trading Up 1.6 %

The firm’s 50 day moving average price is $21.55 and its two-hundred day moving average price is $15.64.

Insider Transactions at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, Director Louis G. Lange bought 5,000 shares of the firm’s stock in a transaction dated Tuesday, February 13th. The stock was acquired at an average price of $19.00 per share, for a total transaction of $95,000.00. Following the completion of the purchase, the director now owns 24,878 shares of the company’s stock, valued at $472,682. The acquisition was disclosed in a filing with the SEC, which is available through this link. In other NewAmsterdam Pharma news, Director Louis G. Lange bought 5,000 shares of the firm’s stock in a transaction dated Tuesday, February 13th. The stock was acquired at an average price of $19.00 per share, for a total transaction of $95,000.00. Following the completion of the purchase, the director now owns 24,878 shares of the company’s stock, valued at $472,682. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, Director James N. Topper bought 8,429 shares of the firm’s stock in a transaction dated Tuesday, March 26th. The shares were acquired at an average price of $21.50 per share, with a total value of $181,223.50. Following the purchase, the director now directly owns 3,008,429 shares of the company’s stock, valued at approximately $64,681,223.50. The disclosure for this purchase can be found here. Insiders own 2.50% of the company’s stock.

Institutional Investors Weigh In On NewAmsterdam Pharma

A number of hedge funds have recently added to or reduced their stakes in the company. Wolverine Asset Management LLC acquired a new stake in NewAmsterdam Pharma in the third quarter valued at about $27,000. Schonfeld Strategic Advisors LLC lifted its position in NewAmsterdam Pharma by 12.9% in the third quarter. Schonfeld Strategic Advisors LLC now owns 64,700 shares of the company’s stock valued at $598,000 after purchasing an additional 7,400 shares during the period. Yarbrough Capital LLC acquired a new stake in NewAmsterdam Pharma in the first quarter valued at about $567,000. Affinity Asset Advisors LLC lifted its position in NewAmsterdam Pharma by 25.0% in the third quarter. Affinity Asset Advisors LLC now owns 125,000 shares of the company’s stock valued at $1,156,000 after purchasing an additional 25,000 shares during the period. Finally, Parkman Healthcare Partners LLC lifted its position in NewAmsterdam Pharma by 20.8% in the fourth quarter. Parkman Healthcare Partners LLC now owns 300,750 shares of the company’s stock valued at $3,359,000 after purchasing an additional 51,726 shares during the period. Institutional investors and hedge funds own 89.89% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.